Keloid
5
Pipeline Programs
3
Companies
3
Clinical Trials
1 recruiting
1
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
2
0
0
2
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Monoclonal Antibody
267%
Small Molecule
133%
+ 1 programs with unclassified modality
On Market (1)
Approved therapies currently available
Competitive Landscape
3 companies ranked by most advanced pipeline stage
RegeneronTARRYTOWN, NY
2 programs1
1
DupilumabPhase 4Monoclonal Antibody
DupilumabPhase 2Monoclonal Antibody1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
PfizerRitlecitinib
RegeneronDupilumab
OrganogenesisApligraf
Clinical Trials (3)
Total enrollment: 50 patients across 3 trials
Ritlecitinib in Patients With Keloids or Those Undergoing Keloidectomy
Start: Aug 2024Est. completion: Aug 202730 patients
Phase 2Recruiting
Study to Assess Efficacy and Safety of Dupilumab in the Treatment of Keloids
Start: Jan 2023Est. completion: Jun 202520 patients
Phase 2Completed
A Pilot Study of Apligraf for the Treatment and Prevention of Recurrence of Excised Keloids
Start: Dec 2007Est. completion: Mar 2010
Phase 1/2Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 50 patients
Monoclonal Antibody is the dominant modality (67% of programs)
3 companies competing in this space